Form 4: Emergent BioSolutions Director Neal Franklin Fowler Reports Stock and Option Grants

Director Neal Franklin Fowler reports receiving stock options and restricted stock units (RSUs) from Emergent BioSolutions as part of annual compensation for board service.

Summary

• On May 23, 2024, Neal Franklin Fowler, a director of Emergent BioSolutions Inc., reported transactions related to the company's stock.
• Fowler received 17,430 restricted stock units (RSUs) and 25,748 stock options as part of his annual compensation for board and committee service.
• The RSUs represent the right to receive one share of Emergent BioSolutions common stock upon vesting, which occurs on the day prior to the one-year anniversary of the grant date, contingent on Fowler remaining a board member.
• The stock options also vest on the same date and allow Fowler to purchase one share of common stock at an exercise price of $5.02.
• Following these transactions, Fowler beneficially owns 136,100 shares of Emergent BioSolutions common stock and 25,748 stock options.
• The number of options granted was determined by dividing half of the total non-employee director compensation value by the Black-Scholes value of a single option calculated as of the date of the grant.

Sentiment

Score: 7

Explanation: The document reflects a routine grant of stock options and RSUs to a director, indicating standard corporate governance practices. The sentiment is neutral to slightly positive as it aligns director interests with shareholder value.

Positives

• The grant of RSUs and stock options aligns the director's interests with those of the shareholders.
• The vesting requirements incentivize continued service on the board of directors.

Future Outlook

The RSUs and stock options will vest on the day prior to the one-year anniversary of the grant date, subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date.

Industry Context

Granting stock options and RSUs to board members is a common practice in the biopharmaceutical industry to align their interests with those of shareholders and incentivize long-term value creation.

Comparison to Industry Standards

• Stock option grants to non-employee directors are common across the biotechnology industry.
• Companies like Moderna and BioNTech also use equity-based compensation for their board members.
• The specific value and vesting schedules can vary based on company size, performance, and industry benchmarks.

Stakeholder Impact

• Shareholders: The equity grants align the director's interests with those of shareholders, incentivizing value creation.
• Employees: The grants are part of the overall compensation structure, which can impact employee morale and retention.

Key Dates